Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Sylvain Garciaz, Sarah Bertoli, David A Sallman, Justine Decroocq, Pierre-Yves Dumas, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Ludovic Gabellier, Marie Anne Hospital, Ariane Mineur, Arnaud Pigneux, Norbert Vey, Christian Récher

Blood (2023) 142 (Supplement 1): 161.

https://doi.org/10.1182/blood-2023-185437

Published: 2023

Journal Articles

Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Sylvain Garciaz, Pierre Bories, Jean-Marie Boher, Marie Anne Hospital, Christian Récher, Colombe Saillard, Yosr Hicheri, Coralie Belanger, Renato Monteiro, Olivier Hermine, Pierre Launay, Norbert Vey

Blood (2023) 142 (Supplement 1): 4290.

https://doi.org/10.1182/blood-2023-185717

Published: 2023

Journal Articles

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2023-173302

Published: 2023

Journal Articles

CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2023-184591

Published: 2023

Journal Articles

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2023-173413

Published: 2023

Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood (2023) 142 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2023-173162

Published: 2023

Journal Articles

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Blood (2023) 142 (Supplement 1): 57.

https://doi.org/10.1182/blood-2023-172422

Published: 2023

Journal Articles

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Blood (2023) 142 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2023-180733

Published: 2023

Journal Articles

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Blood (2023) 142 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2023-181673

Published: 2023

Journal Articles

Evaluation of ICT01, a γ9δ2 T Cell-Activating Monoclonal Antibody, Combined with Venetoclax and Azacitidine in 1L AML (EVICTION Study)

Elisabeth Wieduwild, Anne-Charlotte Le Floch, Céline Garulli, Caroline Imbert, Aude De Gassart, Patrick Brune, Katrien Lemmens, Sylvain Garciaz, Abhishek Maiti, Pierre Peterlin, Celine Leparquier, Marina Iche, Norbert Vey, Daniel Olive, Paul Frohna

Blood (2023) 142 (Supplement 1): 1552.

https://doi.org/10.1182/blood-2023-189936

Published: 2023

Journal Articles

Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

Blood (2023) 142 (Supplement 1): 6483.

https://doi.org/10.1182/blood-2023-186086

Published: 2023

Journal Articles

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blood (2022) 140 (Supplement 1): 12335–12338.

https://doi.org/10.1182/blood-2022-163478

Published: 2022

Journal Articles

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Anthony S. Stein, Ashish Bajel, Shaun Fleming, Mojca Jongen-Lavrencic, Sylvain Garciaz, Abhishek Maiti, Nicolas Boissel, Stephane De Botton, Gerwin A. Huls, David C. de Leeuw, David Avigan, Kyle Jensen, Brigitte Demers, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Andrew H Wei

Blood (2022) 140 (Supplement 1): 7476–7477.

https://doi.org/10.1182/blood-2022-166000

Published: 2022

Journal Articles

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

Sylvain Garciaz, Yves Collette, Remy Castellano, Michel Aurrand-Lions, Helene Sicard, Laetitia Jentreau, Norbert Vey, Cecile Bougeret

Blood (2022) 140 (Supplement 1): 7800–7801.

https://doi.org/10.1182/blood-2022-166820

Published: 2022

Journal Articles

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Sylvain Garciaz, Justine Decroocq, Sarah Bertoli, Amine Belhabri, Pierre-Yves Dumas, Celestine Simand, Kamel Laribi, Alberto Santagostino, Martin Carre, Aline Schmidt, Gaspard Aspas Requena, Chantal Himberlin, Marie-Anne Hospital, Christian Recher, Norbert Vey

Blood (2022) 140 (Supplement 1): 6147–6148.

https://doi.org/10.1182/blood-2022-158247

Published: 2022

Journal Articles

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Blood (2021) 138 (Supplement 1): 267.

https://doi.org/10.1182/blood-2021-145424

Published: 2021

Journal Articles

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Sylvain Garciaz, Marie Anne Hospital, Colombe Saillard, MD, Yosr Hicheri, Evelyne D'Incan, Jerome Rey, Catherine Lacombe, Arnaud Pigneux, MD PhD, Marie-Christine Béné, PharmSciD, PhD, Christian Recher, MD PhD, Marie-Joelle Mozziconacci, Norbert Vey, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141229

Published: 2020

Journal Articles

Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia

Sylvain Garciaz, Amel Soua, Ilhem Rahal, Marie Anne Hospital, Colombe Saillard, MD, Yosr Hicheri, Bilal Mohty, MD, Evelyne D'Incan, Jerome Rey, MD, Norbert Vey, MD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-139918

Published: 2020

Journal Articles

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139971

Published: 2020

Journal Articles

Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers

Blood (2017) 130 (Supplement 1): 652.

https://doi.org/10.1182/blood.V130.Suppl_1.652.652

Published: 2017

NARROW

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Evaluation of ICT01, a γ9δ2 T Cell-Activating Monoclonal Antibody, Combined with Venetoclax and Azacitidine in 1L AML (EVICTION Study)

Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only